e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Idiopathic pulmonary fibrosis (IPF): treatment highlights
Login
Advanced search
e-learning
resources
COVID-19
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
Global Lung Function Initiative
e-learning
Case reports
CME Online
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
VALUE-Dx
Courses and events
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data
K. Karagiannis (Rhodes, Greece)
Source:
International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Session:
Idiopathic pulmonary fibrosis (IPF): treatment highlights
Session type:
Oral Presentation
Number:
3397
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Karagiannis (Rhodes, Greece). Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data. 3397
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension
Diagnosis and treatment of chronic pulmonary embolism
The diagnosis of pulmonary hypertension
COVID-19
Disease Areas
Events
Publications
Guidelines
e-learning
VALUE-Dx
Login